L-Arginine, Vascular Response and Mechanisms

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01482247

Enrollment

Registered

2011-11-30

Start date

2012-04-30

Completion date

2014-01-31

Last updated

2016-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypertension

Brief summary

The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).

Interventions

DIETARY_SUPPLEMENTL-Arginine

Dietary Supplement

DIETARY_SUPPLEMENTPlacebo Supplement

Dietary Supplement

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Healthy volunteers

Inclusion criteria

* diabetes and/or hypertension

Exclusion criteria

* alzheimers disease, dementia, stroke, active herpes, recent angina or heart attack

Design outcomes

Primary

Measure	Time frame
Functional transcranial doppler measures	6 weeks

Secondary

Measure	Time frame
Flow Mediated Dilation (FMD)	6 weeks
Finger Blood Flow - Plethysmography (PAT)	6 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026